Another Risperdal gynecomastia lawsuit settled last month in Pennsylvania, just before the case was scheduled to go to trial in the Philadelphia Court of Common Pleas. Terms of this most recent settlement remain confidential, and neither Johnson & Johnson nor its Janssen Pharmaceuticals unit have admitted to any liability in agreeing to resolve the case.

This is the second time this year that a Pennsylvania Risperdal lawsuit involving male breast growth has settled just prior to trial. In May, another undisclosed agreement was struck in Moffat v. Janssen Pharmaceuticals the same day opening arguments were to get underway. This latest case, N.F. v. Janssen Pharmaceuticals, was resolved just days before its October 31st trial date.

Despite these agreements, a global settlement of the Risperdal litigation, which currently includes more than 2,000 Pennsylvania lawsuits and thousands of other cases pending in courts around the U.S., does not appear to be on the horizon.

“Throughout the history of the litigation there have been occasions where both sides have been able to work out a settlement, and this is one of those times,” a plaintiff’s attorney recently told The Legal Intelligencer. “The recent settlements are more of an exception than the rule, and we look forward to getting to present the next case to a jury in December.”

Other Risperdal Verdicts

Over the past two years, the Pennsylvania litigation has been convening trials for Risperdal lawsuits that involve gynecomastia. The most recent case concluded in July, with $70 million in compensatory damages awarded to a teenager who developed female-like breasts after he began taking the antipsychotic medication in 2003.

In three of the state’s four additional Risperdal gynecomastia trials, juries have awarded plaintiffs damages amounting to $2.5 million, $1.75 million and $500,000. The jury in the fourth case declined to award any damages to the plaintiff, after determining that Risperdal did not cause his breast growth. However, the panel did find that the drug’s manufacturers failed to adequately warn patients and doctors about the drug’s risks.

At least 10 more Risperdal lawsuits that involve male breast growth are slated to go to trial in Pennsylvania. A California litigation that includes about 300 gynecomastia claims will also begin  sending cases to juries in the coming months.

Bernstein Liebhard LLP continues to investigate lawsuits involving Risperdal and male breast growth. If you are interested in joining this litigation, please call 1-877-779-1414.

Published November 22, 2016 by